Aerie Pharma (AERI) Misses Q3 EPS by 35c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Aerie Pharma (AERI) Misses Q3 EPS by 35c

Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

November 6, 2018 4:01 PM EST

Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the third quarter ended September30, 2018, along with a general business update.

Aerie Highlights

Rhopressa® (netarsudil ophthalmic solution) 0.02% generated third quarter net revenues on a U.S. GAAP (generally accepted accounting... More